Acrivon Therapeutics
ACRV
Acrivon Therapeutics (ACRV) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.47
- EPS estimate
- −$0.59
- EPS surprise
- +20.49%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 13, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 13, 2025 | −$0.59 | −$0.47 | +20.49% | $0.00 | SEC |
| Q2 2025 | Aug 13, 2025 | −$0.57 | −$0.55 | +3.13% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.64 | −$0.51 | +20.62% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.66 | −$0.60 | +9.58% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.58 | −$0.59 | −2.01% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.60 | −$0.52 | +13.71% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.84 | −$0.73 | +13.07% | $0.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.73 | −$0.86 | −18.13% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.71 | −$0.66 | +6.82% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$0.65 | −$0.63 | +2.78% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.65 | −$0.58 | +10.84% | $0.00 | SEC |
| Q4 2022 | Mar 28, 2023 | −$0.81 | −$0.80 | +1.23% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Acrivon Therapeutics (ACRV) last report earnings?
Acrivon Therapeutics last reported on Nov 13, 2025, covering fiscal Q3 2025.
Did ACRV beat earnings estimates?
Yes. Acrivon Therapeutics reported EPS of −$0.47 for Q3 2025 against a −$0.59 estimate — a 20.49% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.